Title
Acute Gastroenteritis Morbidity and Mortality Trends Following Universal Rotavirus Vaccination in Children in Peru: Ecological Database Study with Time-Trend Analysis
Date Issued
01 December 2021
Access level
open access
Resource Type
journal article
Author(s)
Publisher(s)
Adis
Abstract
Introduction: Rotavirus (RV) infection is the leading cause of severe diarrhea in children worldwide. It is responsible for around 25% of gastroenteritis (GE) cases, 33% of hospitalized GE cases, and an annual mortality rate of 113.4/100,000 in children < 5 years of age in Peru. RV infant vaccination is recommended by the World Health Organization and provides the best public health strategy to manage the disease. Universal RV vaccination was introduced in Peru in 2009. Methods: Trends in GE ambulatory visits, hospitalizations, and deaths in children < 5 years of age are described in the pre-vaccination (2004–2008) versus post-vaccination (2010–2018) periods. Time-trend analysis was performed (using generalized linear regression models) to assess the impact of vaccination nationwide and by region after adjusting for variables. Results: Between 2009 and 2011, vaccination coverage increased to over 80% in Peru. In infants < 1 year of age, GE ambulatory cases, hospitalizations, and deaths decreased in the post-vaccination period by 40.3%, 46.2%, and 55.5%, respectively (and in children < 5 years of age, by 34.4%, 41.9%, and 54.3%, respectively) compared with the pre-vaccination period. Results of the multivariate time-trend analysis also found significant decreases in the post-vaccination period of 10.7% (GE ambulatory cases), 17.2% (GE hospitalizations), and 37.3% (GE mortality) in children < 5 years of age. Data analyzed by region varied, with Costa and Sierra regions generally in line with the national findings; however, some findings were less robust for Selva due to fewer available data. Conclusion: After 9 years of RV vaccination in Peru, there appears to be a statistically significant positive impact of vaccination, in terms of reducing GE-related mortality, hospitalizations, and ambulatory visits in infants and young children. For policymakers to understand regional differences and future vaccination needs, continued improvement in surveillance is needed. Graphical Abstract: [Figure not available: see fulltext.]
Start page
2563
End page
2574
Volume
10
Issue
4
Language
English
OCDE Knowledge area
Ciencias médicas, Ciencias de la salud
Subjects
Scopus EID
2-s2.0-85114318711
Source
Infectious Diseases and Therapy
ISSN of the container
21938229
Sponsor(s)
GlaxoSmithKline Biologicals SA funded this study (HO-18-19106) and took in charge all costs associated with the development and publication of this manuscript. The authors would like to thank David Iglesias, Maria Mercedes Castrejon and Maria Gabriela Graña for the support in the conception of the study. The authors would also like to thank the Business & Decision Life Sciences platform for editorial assistance and manuscript coordination, on behalf of GSK. Maxime Bessières coordinated manuscript development and editorial support and Kavi Littlewood (Littlewood Writing Solutions) provided writing support. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. CV, PJ and TO were involved in the conception and/or the design of the study. CV, PJ and AGH participated in the data collection/generation of the study data. AGH, PJ, VG, CV and VP were involved in the interpretation of the data. All authors reviewed and approved the final manuscript. AGH and PJ are employed by the GSK group of companies. PJ holds shares in the GSK group of companies. VP was previously an employee of Merck Sharp & Dohme and is now an employee of the GSK group of companies. AGH, PJ and VP declare no other financial and non-financial relationships and activities. TO and VG declare no financial and non-financial relationships and activities and no conflicts of interest. This study used anonymized aggregated database data with no personally identifiable information which can be linked to a patient. It was therefore considered out of scope for ethics review based on Peru’s law on Transparency and Access to Information (Law 27,806). The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. The datasets were formally solicited from the main data sources outlined in Supplementary Table 1. Rotarix is a trademark owned by or licensed to the GSK group of companies. RotaTeq is a trademark owned by or licensed to Merck Sharp & Dohme Corp.
Sources of information:
Directorio de Producción Científica
Scopus